Article Details

BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral ...

Retrieved on: 2022-09-10 18:28:22

Tags for this article:

Click the tags to see associated articles and topics

BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral .... View article details on hiswai:

Excerpt

Tislelizumab is a humanized IgG4 anti-PD-1 monoclonal antibody ... anti-tumor activity of PD-1 antibodies through activation of antibody-dependent ...

Article found on: markets.financialcontent.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up